-
公开(公告)号：US11773178B2
公开(公告)日：2023-10-03
申请号：US17588518
申请日：2022-01-31
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C12N15/63 , C07K16/28 , A61K39/395 , A61K47/68 , C07K16/46 , A61P37/00 , A61K45/06 , A61K39/00 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803 , A61K2039/505 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US10556948B2
公开(公告)日：2020-02-11
申请号：US15364612
申请日：2016-11-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mohan Srinivasan , Shrikant Deshpande , Qihong Zhao , Huadong Sun , Ginger Rakestraw , Guodong Chen , Richard Y. Huang , Steven Sheriff , Cristian Rodriguez , John P. Throup , Rose A. Dibella
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
公开(公告)号：US12173069B2
公开(公告)日：2024-12-24
申请号：US16982277
申请日：2019-03-19
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US11254750B2
公开(公告)日：2022-02-22
申请号：US17080626
申请日：2020-10-26
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C07K16/28 , A61K39/395 , C07K16/46 , A61P37/00 , A61K47/68 , A61K45/06 , A61K39/00 , C07K14/705
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US11261258B2
公开(公告)日：2022-03-01
申请号：US16686596
申请日：2019-11-18
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: A61K39/395 , C07K16/28 , A61K47/68 , C07K16/46 , C07K14/705 , A61K45/06 , A61K39/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20210017283A1
公开(公告)日：2021-01-21
申请号：US16982277
申请日：2019-03-19
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US20200055936A1
公开(公告)日：2020-02-20
申请号：US16493712
申请日：2018-03-13
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC: C07K16/28
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US12091462B2
公开(公告)日：2024-09-17
申请号：US17258866
申请日：2019-07-10
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
CPC classification number: C07K16/2827 , A61P35/00 , A61K2039/507 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US11926673B2
公开(公告)日：2024-03-12
申请号：US17579468
申请日：2022-01-19
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: A61K39/395 , A61K47/68 , A61P37/00 , C07K16/28 , C07K16/46 , C12N15/63 , A61K39/00 , A61K45/06 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K2039/505 , A61K45/06 , A61K47/6803 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US11708405B2
公开(公告)日：2023-07-25
申请号：US16728757
申请日：2019-12-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mohan Srinivasan , Shrikant Deshpande , Qihong Zhao , Huadong Sun , Ginger Rakestraw , Guodong Chen , Richard Y. Huang , Steven Sheriff , Cristian Rodriguez , John P. Throup , Rose A. Dibella
CPC classification number: C07K16/24 , A61K9/0019 , A61K47/6845 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
